Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Rhea-AI Summary

Danaher (NYSE: DHR) has launched a collaboration with Johns Hopkins University to develop new methods for diagnosing mild Traumatic Brain Injury (TBI) using blood-based biomarkers. The partnership aims to improve the detection of specific biomarkers found in blood when brain cells are damaged, potentially leading to earlier and more precise diagnosis of TBI and improved treatment outcomes. The research, led by experts from Johns Hopkins School of Nursing and Johns Hopkins Medicine, leverages technology from Beckman Coulter Diagnostics, a Danaher subsidiary.

Positive

• The collaboration between Danaher and Johns Hopkins University aims to develop new methods for diagnosing mild TBI using blood-based biomarkers, potentially leading to earlier and more precise diagnosis.

• The project seeks to leverage cutting-edge technology from Beckman Coulter Diagnostics to detect specific biomarkers in blood, improving the detection of brain cell damage and enhancing treatment outcomes for patients.

• The research, led by experts from Johns Hopkins University, could potentially be adapted for the diagnosis of other types of brain injuries or neurodegenerative diseases, expanding the impact of the collaboration.

Negative

• Current methods for diagnosing mild TBI, such as CT scans, have limitations in effectively identifying patients at risk of developing incapacitating symptoms. The need for a more precise diagnostic approach remains a challenge in the field.

• While the collaboration shows promising potential for improving TBI diagnosis, the effectiveness of the new methods and their scalability for widespread application remain to be validated through research and clinical trials.

• The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely.
• Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics.
• This approach could potentially be adapted for diagnosis of other neurological conditions.

WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.

Julie Sawyer Montgomery, Vice President and Group Executive, Danaher Diagnostics, said: "Our latest in vitro diagnostics innovations are improving the detection of specific biomarkers found in blood when brain cells are damaged. We are thrilled to partner with Johns Hopkins with the goal of leveraging these solutions to develop tests for earlier and more precise diagnosis of mild TBI, which could ultimately lead to improved treatment outcomes and faster recovery for patients."

Nearly 56 million mild TBI patients worldwide could benefit from a more precise approach to diagnosis¹. While computed tomography (CT) is used to visualize tissue damage and diagnose moderate to severe TBI, mild TBI correlates poorly with abnormalities on head CTs². Doctors therefore need a better way to decide which patients should undergo a CT scan and identify patients who have a higher risk of developing incapacitating symptoms.

The Beacon builds on recent neurological biomarker research³ and next-generation immunoassay detection technology developed by Beckman Coulter Diagnostics. If effective, the approach could potentially be adapted for the diagnosis of other types of brain injury or neurodegenerative diseases. The research will be led by Jessica Gill, PhD, MSN, BSN, RN, Professor at the Johns Hopkins School of Nursing and Richard Rothman, MD, PhD, Professor of Emergency Medicine at Johns Hopkins Medicine.

The Danaher Beacon for Brain Injury Diagnostics is the sixth collaboration in the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.  Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies.  Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

FORWARD-LOOKING STATEMENTS 
Statements in this release that are not strictly historical, including any statements regarding events or developments that Danaher believes or anticipates will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2024.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. 

Sources

1. https://nap.nationalacademies.org/catalog/25394/traumatic-brain-injury-a-roadmap-for-accelerating-progress
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469272
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359936/

View original content:https://www.prnewswire.com/news-releases/danaher-launches-collaboration-with-johns-hopkins-university-aiming-to-improve-neurological-diagnosis-302140906.html

SOURCE Danaher Corporation

FAQ

What is the collaboration between Danaher and Johns Hopkins University about?

Danaher and Johns Hopkins University are collaborating to develop new methods for diagnosing mild Traumatic Brain Injury (TBI) using blood-based biomarkers.

What technology is being used in the collaboration?

Cutting-edge technology from Beckman Coulter Diagnostics, a Danaher subsidiary, is being leveraged in the collaboration to detect specific biomarkers in blood.

Who is leading the research in the collaboration?

Experts from Johns Hopkins School of Nursing and Johns Hopkins Medicine are leading the research in the collaboration.

What is the potential impact of the research collaboration?

The research could potentially lead to earlier and more precise diagnosis of mild TBI, improved treatment outcomes, and the development of diagnostic methods for other brain injuries and neurodegenerative diseases.